AI Index / Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX)
Recursion is integrating AI in drug discovery through automated synthesis platforms and active learning for precision chemistry and biology. The company relies on technology-enabled drug discovery processes to enhance efficiency in identifying novel drugs. The company is leveraging technology for precision chemistry and biology, aiming to reduce the time and cost of drug development. Recursion has several partnerships, including with NVIDIA and Exscientia to enhance capabilities in generative AI for molecular design.
Loading...
The first is our causal AI applied to human genomics.
- Christopher C. Gibson
Similar Companies in the Swift AI Index
Quotes from recursion-pharmaceuticals Executives About Artificial Intelligence and Generative AI
At Recursion, we base everything off of proprietary fit-for-purpose data, whether it's data we generate in-house or data that we pull from partners.
- Christopher C. Gibson
Another area we've been talking about for the last year has been our ClinTech platform. And this is something that we are now deploying against every single one of our programs at Recursion.
- Christopher C. Gibson
We're combining that with our perturbation biology data and algorithms from Recursion to help to connect our platform to patients. And this is enabling us to identify targets, to stratify patients, and even to do indication expansion.
- Christopher C. Gibson
And third, we're now using our AI, not just to identify patients, not just to design our clinical trials, but actually to recruit and execute.
- Christopher C. Gibson
On the partnership front, I get this question a lot. So I just wanted to step back for a second and share. Across our partnerships, there's 2 major areas of value creation. The first is really around what Chris mentioned in the beginning, proprietary fit-for-purpose data sets that we're co-developing with our partners.
- Najat Khan
On the partnership front, I get this question a lot. So I just wanted to step back for a second and share. Across our partnerships, there's 2 major areas of value creation. The first is really around what Chris mentioned in the beginning, proprietary fit-for-purpose data sets that we're co-developing with our partners.
- Najat Khan
And the other area of value creation is around partner programs where we are designing using our AI modules on the chemistry side, very challenging first-in-class, best-in-class programs.
- Najat Khan
The last question was about Boltz-2. Boltz-2 was a really exciting partnership with both MIT and Nvidia, where we were able to help lead the field of protein folding and lead the field of protein ligand binding predictions.
- Christopher C. Gibson
Another area we've been talking about for the last year has been our ClinTech platform. And this is something that we are now deploying against every single one of our programs at Recursion.
- Christopher C. Gibson
Our commitment as a management team to making sure that we're doing this as efficiently as possible.
- Ben R. Taylor
One of the components for designing high permeability, rapid absorption, and low efflux was to ensure that we would have sufficient exposures.
- Najat Khan
What ambitious or transformative initiatives are you planning to reflect your next level of thinking? First, I'd just say, if you looked at the State of AI Report that Nathan Benaich puts out, you'll actually see that Recursion is, I believe, one of the only biopharma companies that's actually listed as the top 20 private or public companies in the world.
- Christopher C. Gibson
I think one point to note here, it's a real pleasure and honor to partner with partners such as Roche, Sanofi, Bayer and Merck KgAa...
- Najat Khan
Boltz-2... we're able to actually make binding predictions that are approaching the level of efficiency and the level of efficacy of free energy perturbation calculations, but we're able to do this with about 1,000-fold less compute.
- Christopher C. Gibson
RBM39 inhibitors or degraders could potentially provide a druggable potential analog.
- Najat Khan
One last comment on Boltz-2... this is the partnership that we alluded to at JPMorgan. And one of the questions here is why open source versus keeping it internal?
- Christopher C. Gibson